Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions

Abstract

Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.

1 .- 9 . (canceled) 
     
     
         10 . A method for the treatment of skin tumor lesion and virus induced skin disease, comprising topical administration of the composition comprising between 0.01% -1% resiquimod, said composition being effective to reduce or eliminate said lesion or disease while limiting adverse skin reactions selected from erythema and inflammation, said composition reducing tumor lesion penetration into surrounding tissue and metastasis to lymph nodes. 
     
     
         11 . The method of  claim 10 , wherein said skin tumor lesion is a precancerous pigmented lesion selected from an atypical melanocytic lesions, atypical melanocytic hyperplasia, atypical intraepidermal melanocytic hyperplasia, atypical intraepidermal melanocytic proliferation and actinic keratosis. 
     
     
         12 . The method of  claim 10  wherein said lesion is selected from lentigo maligna, melanoma in situ, squamous cell carcinoma in situ, said composition being effective to reduce local tissue invasion. 
     
     
         13 . The method of  claim 10  wherein said lesion is indicative of primary invasive melanoma, basal cell carcinoma, or a squamous cell carcinoma, said composition being effective to reduce infiltration through tissues and reduce metastasis to lymph nodes. 
     
     
         14 . The method of  claim 10  wherein said lesion is selected from Bowen's disease, squamous cell carcinoma in situ, arsenical keratosis, radiation keratosis, PUNA keratosis, bowenoid papulosis, sebaceous carcinoma, porocarcinoma, extramammary Paget's disease, Merkel cell carcinoma and cutaneous T cell lymphoma. 
     
     
         15 . The method of  claim 10  for the treatment of epidermal keratinocyte proliferation, and seborrheic keratosis. 
     
     
         16 . The method of  claim 10 , wherein said virus induced skin disease is selected from molluscum contagiosum, fIPV infection, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia., common warts, and RSV infection. 
     
     
         17 .- 20 . (canceled) 
     
     
         21 . The method of  claim 10 , said treatment further comprising systemic administration of at least one immune modulator selected from anti-PD1, anti-PDL1, Anti-CTLA-4 antibody, anti-CD137 antibody, agonistic CD40 antibody, CD134 (Anti-OX40) agonist and PLX3397. 
     
     
         22 . The method of  claim 10 , further comprising systemic administration of interferon gamma. 
     
     
         23 . The method of  claim 10 , further comprising of administration of local radiation with or without systemic anti-PD1 antibody. 
     
     
         24 . The method of  claim 10 , further comprising of administration of photodynamic therapy. 
     
     
         25 . The method of  claim 10 , wherein said composition comprises a filler. 
     
     
         26 . The method of  claim 25 , wherein said filler is a dermal filler. 
     
     
         27 . The method of  claim 25 , wherein said dermal filler is at least one of hydroxylapatite, sodium hyaluronate, poly-L-lactic acid, collagen and hydrogel. 
     
     
         28 . The method of  claim 25  wherein said filler is purified oil. 
     
     
         29 . The method of  claim 28 , wherein said purified oil is at least one of soybean oil, triolein, castor oil, fractionated coconut oil, miglyol 810, miglyol 812, Neobee MS or Captex 300.